scispace - formally typeset
Open AccessJournal ArticleDOI

Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma

TLDR
The data suggest that BRAF V600E mutation is associated with high-risk PTC and in particular in follicular variant with invasive tumor growth.
Abstract
Context: Because very few studies have examined the correlation between BRAF mutations and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a large and homogeneous cohort of patients with PTC for the presence of the BRAF mutation. Objective: We examined BRAF mutations in a consecutive series of 500 PTC patients who underwent surgery in the Department of Surgery of the University of Pisa, and we correlated the presence of the mutation with clinicopathological parameters of the patients: age, gender, tumor size, presence of tumor capsule, extrathyroidal invasion, multicentricity, presence of node metastases, and tumor class. Design: BRAF (exon 15) mutation was examined by PCR-single strand conformational polymorphism followed by DNA sequencing in laser-capture microdissected tissue samples. Results: In this study, BRAF mutation was found in 219 of 500 cases (43.8%). In particular, we found the most common BRAF V600E mutation in 214 cases (42.8%), BRAF K601E mutation in thr...

read more

Citations
More filters
Journal ArticleDOI

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors

TL;DR: Thyroid tumors currently diagnosed as noninvasive EFVPTC have a very low risk of adverse outcome and should be termed NIFTP, and this reclassification will affect a large population of patients worldwide and result in a significant reduction in psychological and clinical consequences associated with the diagnosis of cancer.
Journal ArticleDOI

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

TL;DR: It has become clearer that BRAF mutation will likely have significant impact on the clinical management of PTC and new mitogen extracellular kinase (MEK) inhibitors developed recently are particularly promising therapeutic agents for thyroid cancer.
Journal ArticleDOI

Molecular genetics and diagnosis of thyroid cancer

TL;DR: Somatic mutations and other molecular alterations have been recognized as helpful diagnostic and prognostic markers for thyroid cancer and are beginning to be introduced into clinical practice, to offer a valuable tool for the management of patients with thyroid nodules.
Journal ArticleDOI

Thyroid Cancer Epidemiology and Prognostic Variables

TL;DR: This paper will discuss this rising trend in incidence with an analysis of the possible reasons for the increase, and explore the factors that portend a worse prognosis for the individual patient.
References
More filters
Journal ArticleDOI

Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

TL;DR: Following 131I therapy, whether given for thyroid remnant ablation or cancer therapy, recurrence and the likelihood of cancer death were reduced by at least half, despite the existence of more adverse prognostic factors in patients given 131I.
Journal ArticleDOI

Papillary and follicular thyroid carcinoma.

TL;DR: Treatment of recurrences is based mainly on surgery and 131I treatment, and the recent availability of recombinant human thyroid stimulating hormone has greatly improved the quality of the patient's life during follow-up.
Journal ArticleDOI

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy

TL;DR: Thyroxine treatment is highly effective in younger patients with (131)I uptake and with small metastases and should be treated until the disappearance of any uptake or until a cumulative activity of 22 GBq has been administered.
Related Papers (5)